Figure 8.

CXCR1/2 antagonism during influenza A virus (IAV) primary infection did not impair development of adaptive immune responses. Mice were infected with IAV (500 PFU, i.n.) and at 3, 4, 5, and 6 days after infection were treated twice a day with DF2162 (10 mg/kg—oral gavage) or the vehicle of the drug. The animals only received the drug during the IAV infection. After 14 days of IAV infection, mice were euthanized after 14 days of IAV infection and the lungs were collected to access the frequency of T cells—CD45⁺CD3⁺CD4⁺ (A) and CD45⁺CD3⁺CD8⁺ (B) recruited into the lungs. After 2 days of secondary pneumococcal infection at day 14 infected, mice were euthanized to assess antibodies levels (C) in serum. Data are presented as mean ± SEM. **P < 0.01 and ***P < 0.001, when compared with Mock mice or indicated groups and ^#P < 0.05 and ^##P < 0.01 when compared to Flu + Streptococcus pneumoniae group (n = 5–6 mice per group, representative of two independent experiments).